UY33225A - (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)metil)piperidin-1-il)metil)tetrahidro-2h-piran-4-ol, un agonista parcial de receptores 5-ht4 - Google Patents

(r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)metil)piperidin-1-il)metil)tetrahidro-2h-piran-4-ol, un agonista parcial de receptores 5-ht4

Info

Publication number
UY33225A
UY33225A UY0001033225A UY33225A UY33225A UY 33225 A UY33225 A UY 33225A UY 0001033225 A UY0001033225 A UY 0001033225A UY 33225 A UY33225 A UY 33225A UY 33225 A UY33225 A UY 33225A
Authority
UY
Uruguay
Prior art keywords
methyl
iloxi
piran
isoxazol
piperidin
Prior art date
Application number
UY0001033225A
Other languages
English (en)
Spanish (es)
Inventor
Noguchi Hirohide
Waizumi Nobuaki
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY33225A publication Critical patent/UY33225A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY0001033225A 2010-02-16 2011-02-14 (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)metil)piperidin-1-il)metil)tetrahidro-2h-piran-4-ol, un agonista parcial de receptores 5-ht4 UY33225A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30492110P 2010-02-16 2010-02-16

Publications (1)

Publication Number Publication Date
UY33225A true UY33225A (es) 2011-09-30

Family

ID=43904611

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033225A UY33225A (es) 2010-02-16 2011-02-14 (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)metil)piperidin-1-il)metil)tetrahidro-2h-piran-4-ol, un agonista parcial de receptores 5-ht4

Country Status (15)

Country Link
US (1) US20120041026A1 (enExample)
EP (1) EP2536713A1 (enExample)
JP (1) JP2013519722A (enExample)
KR (1) KR20120123089A (enExample)
CN (1) CN102762554A (enExample)
AR (1) AR080172A1 (enExample)
AU (1) AU2011216950A1 (enExample)
CA (1) CA2788656A1 (enExample)
IN (1) IN2012DN06631A (enExample)
MX (1) MX2012008721A (enExample)
SG (1) SG183111A1 (enExample)
TW (1) TW201141856A (enExample)
UY (1) UY33225A (enExample)
WO (1) WO2011101774A1 (enExample)
ZA (1) ZA201206469B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN103702995B (zh) * 2011-05-18 2016-04-13 拉夸里亚创药株式会社 4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式
CA2890861C (en) * 2012-11-21 2021-03-30 Raqualia Pharma Inc. Polymorphic forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
AP2015008742A0 (en) 2013-03-20 2015-09-30 Suven Life Sciences Ltd 5-amino quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
CN105873920B (zh) 2013-12-16 2018-06-08 苏文生命科学有限公司 作为5-ht4受体激动剂的吲唑化合物
JP6572414B2 (ja) * 2014-05-20 2019-09-11 ラクオリア創薬株式会社 ベンズイソオキサゾール誘導体塩
MX368214B (es) 2015-02-13 2019-09-24 Suven Life Sciences Ltd Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).
CN117796401A (zh) * 2023-12-25 2024-04-02 江苏万隆化学有限公司 一种含2-羟基-6-氟苯甲酸甲酯中间体抗菌剂的制备工艺

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU217425B (hu) 1991-02-27 2000-01-28 Merrell Dow Pharmaceuticals Inc. Eljárás NMDA antagonista hatású kinolinszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
CA2149918A1 (en) * 1992-11-23 1994-06-09 Mark G. Palermo Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
CZ292379B6 (cs) 1995-09-29 2003-09-17 Glaxo Wellcome Spa Tetrahydrochinolinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
IL126003A0 (en) 1996-04-10 1999-04-11 Hoechst Marion Roussel Inc Spiro [cyclopent [b] indole-piperidines] and n-[phenyl-hydrazon intermediates for their preparation both being acetyl cholinesterase and mao inhibitors
CA2252039C (en) 1996-04-12 2002-12-24 Hoechst Marion Roussel, Inc. Isatin derivatives as acetylcholinesterase inhibitors and analgesics
AU717431B2 (en) 1996-07-01 2000-03-23 Schering Corporation Muscarinic antagonists
JP3390179B2 (ja) 1996-08-15 2003-03-24 シェーリング コーポレイション エーテルムスカリン様アンタゴニスト
ATE309215T1 (de) 1996-09-30 2005-11-15 Aventis Pharma Inc Nmda (n-methyl-d-aspartate) antagonists
AU758802B2 (en) 1998-09-30 2003-03-27 Takeda Pharmaceutical Company Limited Drugs for improving vesical excretory strength
WO2002059074A1 (en) 2001-01-26 2002-08-01 Sankyo Company, Limited Benzylamine analogue
CA2440284A1 (en) 2001-03-08 2002-09-19 Emory University Ph-dependent nmda receptor antagonists
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
DE60228969D1 (enExample) 2001-07-24 2008-10-30 Richter Gedeon Nyrt
JP3927228B2 (ja) 2003-06-04 2007-06-06 メルク エンド カムパニー インコーポレーテッド Ｎｍｄａ／ｎｒ２ｂ拮抗物質としての３−フルオロ−ピペリジン
GB0316094D0 (en) 2003-07-09 2003-08-13 Neuropharma Sa Acetylcholinesterase dual inhibitors
JP5095388B2 (ja) * 2004-03-03 2012-12-12 ルバンス セラピュティックス インク． ボツリヌストキシンの局所適用及び経皮送達のための組成物及び方法
HU227119B1 (en) 2004-07-29 2010-07-28 Richter Gedeon Nyrt Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them
HU227000B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them
HUP0401522A2 (en) 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
HU226977B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
TW200621677A (en) 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
JP4824693B2 (ja) 2004-10-15 2011-11-30 ユニベルシダデ フェデラル ド リオ デ ジャネイロ ピペリジン誘導体、それを含有する薬剤組成物、及び調製方法
WO2006090224A1 (en) 2005-02-25 2006-08-31 Pfizer Japan Inc. Benzisoxazole derivatives
US20090124600A1 (en) 2005-04-19 2009-05-14 Layton Mark E N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists
WO2007016357A1 (en) 2005-07-29 2007-02-08 Regents Of The University Of Minnesota Amyloid beta receptor and uses thereof
EP2001463B1 (en) 2006-03-20 2013-07-03 Council of Scientific and Industrial Research A pharmaceutical composition useful as acetyl cholinesterase inhibitors
ES2288406B1 (es) 2006-04-20 2008-12-16 Universidad De Barcelona Compuestos inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer.
WO2008074816A1 (en) 2006-12-20 2008-06-26 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
US7605265B2 (en) 2007-01-22 2009-10-20 Biotechnology Research Corporation Ltd. Heterodimers and methods of using them
PL2522668T3 (pl) 2007-05-01 2015-07-31 Concert Pharmaceuticals Inc Związki morfinanu
CN101730706B (zh) 2007-05-11 2015-04-15 生物科技研究有限公司 具有神经保护和增强记忆活性的受体拮抗剂
MX2009014216A (es) 2007-06-29 2010-07-05 Univ Emory Antagonistas del receptor nmda para neuroproteccion.
WO2009036235A2 (en) 2007-09-12 2009-03-19 Virginia Tech Intellectual Properties, Inc. Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (ache)
US8722714B2 (en) 2008-01-16 2014-05-13 The Honk Kong University of Science and Technology Oxazolidine derivatives as NMDA antagonists
EA014100B1 (ru) 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
CN101440061B (zh) 2008-04-08 2010-12-08 温州医学院 一类具有抑制乙酰胆碱酯酶活性的芳基吡啶酮类衍生物
WO2009129181A1 (en) 2008-04-14 2009-10-22 Concert Pharmaceuticals Inc. Propanediol-dicarbamate derivatives
CN102762207A (zh) 2008-05-09 2012-10-31 爱莫里大学 用于治疗神经精神疾患的nmda受体拮抗剂

Also Published As

Publication number Publication date
US20120041026A1 (en) 2012-02-16
AU2011216950A1 (en) 2012-08-23
CA2788656A1 (en) 2011-08-25
KR20120123089A (ko) 2012-11-07
TW201141856A (en) 2011-12-01
AR080172A1 (es) 2012-03-21
CN102762554A (zh) 2012-10-31
MX2012008721A (es) 2012-08-17
SG183111A1 (en) 2012-09-27
WO2011101774A1 (en) 2011-08-25
IN2012DN06631A (enExample) 2015-10-23
JP2013519722A (ja) 2013-05-30
EP2536713A1 (en) 2012-12-26
ZA201206469B (en) 2013-05-29

Similar Documents

Publication Publication Date Title
UY33225A (es) (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)metil)piperidin-1-il)metil)tetrahidro-2h-piran-4-ol, un agonista parcial de receptores 5-ht4
HUS2200033I1 (hu) CGRP receptor antagonisták
PL2513093T3 (pl) Nowi antagoniści receptora CCR2 i ich zastosowanie
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
EA200870409A1 (ru) Антагонисты киназы pi3
EP2083859A4 (en) PCSK9 ANTAGONISTS
EP2083860A4 (en) PCSK9 ANTAGONISTS
EP2480576A4 (en) PCSK9 ANTAGONISTS
IL239604A0 (en) Anti-vegf antibodies and their uses
BRPI1008060A2 (pt) Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo.
EP2470173A4 (en) COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS FROM TAXAN AND HEDGEHOG HEMMERN
ECSP12012034A (es) Antagonistas de pcsk9
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
ES2385606T8 (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
DK2081951T3 (da) Progesteron-receptorantagonister
BRPI1012097A2 (pt) antagonistas e antagonistas inversos de histamina h3 e métodos de uso dos mesmos.
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
EP2365749A4 (en) Quinolone NEURO PEPTIDE-S-Receptor Antagonists
ATE539056T1 (de) Piperidinderivate als agonisten muskariner rezeptoren
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
HUE037300T2 (hu) Szerotonin 5-HT3 receptor antagonisták lezionális vesztibuláris zavarok kezelésében való felhasználásra

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191216